CJ-023,423, a Novel, Potent and Selective Prostaglandin EP4 Receptor Antagonist with Antihyperalgesic Properties

Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction

Yung-Chi Cheng, William H. Prusoff · Biochemical Pharmacology · 1973 · 12.9K citations

Life Sciences, Biochemistry, Chemical Kinetics +14

SOME QUANTITATIVE USES OF DRUG ANTAGONISTS

O. ARUNLAKSHANA, H. O. Schild · British Journal of Pharmacology and Chemotherapy · 1959 · 4K citations · Full text

Medicine, Pharmacology, General Pharmacology +16

Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention

Scott D. Solomon, John J.V. McMurray, Marc A. Pfeffer et al. · New England Journal of Medicine · 2005 · 2.1K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2

Brendan McAdam, Francesca Catella-Lawson, Issam A. Mardini et al. · Proceedings of the National Academy of Sciences · 1999 · 1.3K citations

Medicine, Pharmacology, Pharmacotherapy +13

Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study

David J. Graham, David Campen, Rita L. Hui et al. · The Lancet · 2005 · 912 citations

Medicine, Cardiology, Pharmacology +13